A biotechnology company selected PRA Health Sciences’ Clinical Diagnostic Services (CDS) group to conduct a global diagnostic study, which involved validating innovative, non-invasive blood sample test results collected from high-risk pregnant women against the “gold standard” results from amniocentesis or chorionic villus sampling. To successfully complete the program, the PRA team had to ensure the study tested only high-quality maternal blood samples. Therefore, the study would need to over-enroll for any damaged samples, which would require additional funds.